全视网膜光凝术联合玻璃体腔注射雷珠单抗治疗新生血管性青光眼的效果

doi:10.3760/cma.j.cn441417-20241017-03018

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (3): 440-444.DOI: 10.3760/cma.j.cn441417-20241017-03018

全视网膜光凝术联合玻璃体腔注射雷珠单抗治疗新生血管性青光眼的效果

王燕¹ 姜春辉¹ 景永锋² 崔丽珺³

¹咸阳市中心医院眼科，咸阳 712000；²彬州市中医医院眼科，彬州 713500；³西安交通大学第一附属医院眼科，西安 710061

收稿日期:2024-10-17 出版日期:2025-02-01 发布日期:2025-02-21
通讯作者: 景永锋，Email：jingyongfeng1@qq.com
基金资助:
陕西省重点研发计划（2020SF-265）

Effect of intravitreal injection of Ranibizumab combined with panretinal photocoagulation for neovascular glaucoma

Wang Yan¹, Jiang Chunhui¹, Jing Yongfeng², Cui Lijun³

¹Department of Ophthalmology, Xianyang Central Hospital, Xianyang 712000, China; ²Department of Ophthalmology, Binzhou Hospital of Traditional Chinese Medicine, Binzhou 713500, China; ³Department of Ophthalmology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

Received:2024-10-17 Online:2025-02-01 Published:2025-02-21
Contact: Jing Yongfeng, Email: jingyongfeng1@qq.com
Supported by:
Shaanxi Province Key Research and Development Plan (2020SF-265)

摘要/Abstract

摘要：

目的　探讨全视网膜光凝术联合玻璃体腔注射雷珠单抗治疗新生血管性青光眼（NVG）的效果。方法　选取2020年6月至2023年6月咸阳市中心医院收治的90例NVG患者作为研究对象，均为单眼病变。采用随机数字表法，将患者分为观察组和对照组，各45例。观察组男28例，女17例；年龄24～76（50.62±4.01）岁；患眼：右眼23例，左眼22例；疾病分期：Ⅱ期25例，Ⅲ期20例；病因：视网膜静脉阻塞12例，糖尿病视网膜病变25例，颈动脉狭窄眼缺血综合征8例。对照组男26例，女19例；年龄25～78（51.24±4.32）岁；患眼：右眼21例，左眼24例；疾病分期：Ⅱ期23例，Ⅲ期22例；病因：视网膜静脉阻塞14例，糖尿病视网膜病变24例，颈动脉狭窄眼缺血综合征7例。对照组采用全视网膜光凝术（分4次完成，间隔2 d），观察组在对照组基础上联合玻璃体腔注射雷珠单抗（术前3 d注射1次）。比较两组术后1周临床疗效，术前和术后1周、1个月、6个月眼压和血清长链非编码RNA-肺腺癌转移相关转录因子1（lncRNA MALAT1）水平，术后6个月视力改善情况，术后1个月内并发症发生情况。采用重复测量方差分析、独立样本t检验、配对t检验、χ²检验和秩和检验进行统计学分析。结果　术后1周，观察组治疗总成功率高于对照组［95.56%（43/45）比77.78%（35/45）］（P<0.05）。术后1周、1个月、6个月，观察组眼压均低于对照组［（25.47±4.19）mmHg（1 mmHg=0.133kPa）比（29.59±4.92）mmHg、（20.15±3.42）mmHg比（23.82±4.06）mmHg、（13.01±2.11）mmHg比（17.27±2.65）mmHg］（均P<0.05）；观察组血清lncRNA MALAT1水平均低于对照组［（105.14±11.59）ng/L比（123.26±12.01）ng/L、（84.31±10.89）ng/L比（101.69±11.22）ng/L、（77.26±10.32）ng/L比（91.48±9.53）ng/L］（均P<0.05）。术后6个月，观察组视力改善情况优于对照组（P<0.05）。术后1个月内，两组术后并发症总发生率比较，差异无统计学意义（P>0.05）。结论　全视网膜光凝术联合玻璃体腔注射雷珠单抗治疗NVG效果较好，可改善患者眼压和视力情况，降低血清lncRNA MALAT1水平，安全性较好。

关键词:

青光眼, 新生血管性, 玻璃体腔注射雷珠单抗, 全视网膜光凝术, lncRNA MALAT1

Abstract:

Objective　To investigate the curative effect of intravitreal injection of Ranibizumab combined with panretinal photocoagulation for neovascular glaucoma (NVG). Methods　A total of 90 patients with NVG admitted to Xianyang Central Hospital from June 2020 to June 2023 were selected as the study objects, all of whom were monocular lesions. The patients were divided into an observation group and a control group with 45 cases in each group by the random number table method. There were 28 males and 17 females in the observation group, aged 24-76 (50.62±4.01) years; the affected eye was right eye in 23 cases and left eye in 22 cases; the disease stages were stage Ⅱ in 25 cases and stage Ⅲ in 20 cases; the causes were retinal vein obstruction in 12 cases, diabetic retinopathy in 25 cases, and carotid artery stenosis of eye ischemia syndrome in 8 cases. There were 26 males and 19 females in the control group, aged 25-78 (51.24±4.32) years; the affected eye was right eye in 21 cases and left eye in 24 cases; the disease stages were stage Ⅱ in 23 cases and stage Ⅲ in 22 cases; the causes were retinal vein obstruction in 14 cases, diabetic retinopathy in 24 cases, and carotid artery stenosis of eye ischemia syndrome in 7 cases. The control group was treated with panretinal photocoagulation (a total of 4 times, interval of 2 d), and the observation group was treated with intravitreal injection of Ranibizumab 3 d before surgery on the basis. The clinical efficacy 1 week after surgery, intraocular pressure (IOP) and serum long non-coding RNA- lung adenocarcinoma metastasation-related transcription factor 1 (lncRNA MALAT1) levels before surgery and 1 week, 1 month, and 6 months after surgery, visual acuity improvement 6 months after surgery, and complications within 1 month after surgery were compared between the two groups. Repeated measure ANOVA, independent sample t test, paired t test, χ² test, and rank sum test were used for statistical analysis. Results　One week after surgery, the total treatment success rate of the observation group was higher than that of the control group [95.56% (43/45) vs. 77.78% (35/45)] (P<0.05). One week, one month, and six months after surgery, the IOP of the observation group was lower than that of the control group [(25.47±4.19) mmHg (1 mmHg=0.133 kPa) vs. (29.59±4.92) mmHg, (20.15±3.42) mmHg vs. (23.82±4.06) mmHg, (13.01±2.11) mmHg vs. (17.27±2.65) mmHg] (all P<0.05); the serum lncRNA MALAT1 level in the observation group was lower than that of the control group [(105.14±11.59) ng/L vs. (123.26±12.01) ng/L, (84.31±10.89) ng/L vs. (101.69±11.22) ng/L, (77.26±10.32) ng/L vs. (91.48±9.53) ng/L] (all P<0.05). Six months after surgery, the visual acuity improvement of the observation group was better than that of the control group (P<0.05). There was no statistically significant difference in the total incidence of complications between the two groups within 1 month after surgery (P>0.05). Conclusion　Intravitreal injection of Ranibizumab combined with panretinal photocoagulation is effective in the treatment of NVG, which can improve the patients' IOP and visual acuity, reduce the serum lncRNA MALAT1 level, and has good safety.

Key words:

Glaucoma, Neovascular, Intravitreal injection of Ranibizumab, Panretinal photocoagulation, lncRNA MALAT1

王燕姜春辉景永锋崔丽珺.

全视网膜光凝术联合玻璃体腔注射雷珠单抗治疗新生血管性青光眼的效果 [J]. 国际医药卫生导报, 2025, 31(3): 440-444.

Wang Yan, Jiang Chunhui, Jing Yongfeng, Cui Lijun.

Effect of intravitreal injection of Ranibizumab combined with panretinal photocoagulation for neovascular glaucoma [J]. International Medicine and Health Guidance News, 2025, 31(3): 440-444.

参考文献

[1] 王志军,孙川.新生血管性青光眼的治疗经验与挑战[J].中华眼底病杂志,2021,37(6):415-417.DOI:10.3760/cma.j.cn511434-20210410-00198.
[2] Hwang S, Kim JH, Choi YH, et al. Incidence and risk factor analysis of neovascular glaucoma following vitrectomy in patients with proliferative diabetic retinopathy[J]. Sci Rep, 2024, 14(1):22490. DOI: 10.1038/s41598-024- 73395-8.
[3] 杨海燕,陈凯,周华芬,等.新生血管性青光眼应用小梁切除术,E-PRP联合玻璃体腔注射康柏西普,虹膜周边切除术效果研究[J].重庆医学,2021,50(S2):67-70.
[4] 叶琴,林毓妮,姚贻华,等.巩膜长隧道法Ahmed阀植入术治疗新生血管性青光眼的一年效果观察[J].眼科,2019,28(1):34-38.DOI:10.13281/j.cnki.issn.1004-4469.2019.01.007.
[5] Simha A, Aziz K, Braganza A, et al. Anti-vascular endothelial growth factor for neovascular glaucoma[J]. Cochrane Database Syst Rev, 2020, 2(2):CD007920. DOI: 10.1002/14651858.CD007920.pub3.
[6] 杨清清,李宁.玻璃体腔内注射雷珠单抗在复合式小梁切除术治疗新生血管性青光眼中治疗中的应用效果[J].贵州医药,2023,47(3):422-423.DOI:10.3969/j.issn.1000- 744X.2023.03.050.
[7] 中华医学会眼科学分会青光眼学组.中国新生血管性青光眼诊疗专家共识(2019年)[J].中华眼科杂志,2019,55(11):814-817.DOI:10.3760/cma.j.issn.0412-4081.2019.11.005.
[8] Pirinen I, Leinonen S, Helminen M, et al. Glaucoma progression in patients receiving intravitreal anti-VEGF treatment for neovascular age-related macular degeneration[J]. Acta Ophthalmol, 2023, 101(3):261-265. DOI: 10.1111/aos.15288.
[9] 李洪霞.国际标准视力表[M].南昌:江西科学技术出版社,2010:119-121.
[10] Călugăru D, Călugăru M. Etiology, pathogenesis, and diagnosis of neovascular glaucoma[J]. Int J Ophthalmol, 2022, 15(6):1005-1010. DOI: 10.18240/ijo.2022.06.20.
[11] 夏沁韵,陈震,邢怡桥.新生血管性青光眼治疗进展[J].国际眼科杂志,2020,20(6):987-989.DOI:10.3980/j.issn.1672- 5123.2020.6.13.
[12] Kalogeropoulos D, Moussa G, Sung VC, et al. Neovascular glaucoma: an update[J]. Klin Monbl Augenheilkd, 2023, 240(3):305-315. DOI: 10.1055/a-1956-9348.
[13] 王琳,刘驰.新生血管性青光眼患者实施抗VEGF药物联合PRP治疗的效果研究[J].中国卫生统计,2022,39(5):786-788,791.DOI:10.3969/j.issn.1002-3674.2022.05.035.
[14] Li J, Zhang S, Hou B. Outcomes of vitrectomy, complete pan-retinal photocoagulation, and endoscopic cyclophotocoagulation surgery after anti-VEGF treatment in neovascular glaucoma[J]. Adv Ophthalmol Pract Res, 2023, 3(3):112-118. DOI: 10.1016/j.aopr.2023.05.001.
[15] 严桢桢,石海红.雷珠单抗玻璃体联合巩膜睫状体光凝治疗新生血管性青光眼的疗效分析[J].中国现代医学杂志,2019,29(14):85-88.DOI:10.3969/j.issn.1005-8982.2019. 14.018.
[16] 宋娅琴,马雪英,王笃亲,等.全视网膜光凝技术联合康柏西普对新生血管性青光眼的疗效[J].安徽医科大学学报,2020,55(12):1941-1945.DOI:10.19405/j.cnki.issn1000-1492. 2020.12.024.
[17] Strzalkowski P, Strzalkowska A, Göbel W, et al. Combined vitrectomy, near-confluent panretinal endolaser, bevacizumab and cyclophotocoagulation for neovascular glaucoma - a retrospective interventional case series[J]. F1000Res, 2020, 9:1236. DOI: 10.12688/f1000research.26879.2.
[18] 孙峰,杨学龙,吴兵.雷珠单抗对糖尿病视网膜病变伴新生血管性青光眼的疗效及血清血管内皮生长因子和胰岛素样生长因子-1水平的影响[J].中国医药导报,2023,20(2):118-121.DOI:10.20047/j.issn1673-7210.2023.02.27.
[19] 刘清洋,马萍萍,梁丽银,等.新生血管性青光眼雷珠单抗玻璃体腔注射术后眼压变化趋势[J].广东医学,2020,41(23):2483-2485.DOI:10.13820/j.cnki.gdyx.20201089.
[20] 余萍,刘玲玲,周星利,等.视网膜光凝术联合雷珠单抗治疗新生血管青光眼的疗效及对血液流变学和房水炎性因子的影响[J].现代生物医学进展,2021,21(19):3787-3791.DOI:10.13241/j.cnki.pmb.2021.19.039.
[21] 周晴,谢玉秀,樊秀婷.lncRNA MALAT1在糖尿病新生血管性青光眼虹膜组织中的表达及意义[J].河北医药,2020,42(8):1140-1143.DOI:10.3969/j.issn.1002-7386.2020.08.004.
[22] Zheng M, Zheng Y, Gao M, et al. Expression and clinical value of lncRNA MALAT1 and lncRNA ANRIL in glaucoma patients[J]. Exp Ther Med, 2020, 19(2):1329-1335. DOI: 10.3892/etm.2019.8345.
[23] 冯希敏,赵庆新,张凤妍.雷珠单抗联合小梁切除术及视网膜光凝术治疗新生血管性青光眼临床疗效分析[J].眼科新进展,2018,38(1):80-83.DOI:10.13389/j.cnki.rao.2018.0018.
[24] 易伟,赵洁,杨帆,等.雷珠单抗辅助玻璃体切割术治疗增殖型糖尿病视网膜病变患者的疗效[J].国际医药卫生导报,2024,30(11):1904-1908.DOI:10.3760/cma.j.issn.1007-1245.2024.11.029.
[25] 张旭,黄文志,任国梁,等.雷珠单抗治疗视网膜静脉阻塞黄斑水肿的短期疗效观察及影响因素分析[J].国际医药卫生导报,2021,27(16):2447-2451.DOI:10.3760/cma.j.issn.1007-1245.2021.16.005.

全视网膜光凝术联合玻璃体腔注射雷珠单抗治疗新生血管性青光眼的效果

Effect of intravitreal injection of Ranibizumab combined with panretinal photocoagulation for neovascular glaucoma

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

[1]	辛田杜婷婷武鹏李宁. 手术风险自查护理在青光眼小梁切除术患者中的临床效果 [J]. 国际医药卫生导报, 2024, 30(5): 862-866.
[2]	陈丽丽朱成宝. 眼底激光联合IVR治疗RVO-ME患者的疗效观察 [J]. 国际医药卫生导报, 2023, 29(12): 1703-1707.